Sarepta Therapeutics Inc. (SRPT) Soared To A New High After FDA Approval

Sarepta Therapeutics Inc. (SRPT) spiked dramatically to the upside in early trading Monday, after the FDA granted accelerated approval for EXONDYS 51 for the treatment of Duchenne muscular dystrophy.

from RTT - Before the Bell http://ift.tt/2d1mFM1
via IFTTT